SIH Partners’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$444K Buy
3,130
+47
+2% +$7.56K ﹤0.01% 246
2026
Q2
$520K Hold
3,083
– – ﹤0.01% 236
2026
Q1
$406K Hold
3,083
– – 0.01% 230
2025
Q4
$437K Hold
3,083
– – 0.01% 167
2025
Q3
$433K Hold
3,083
– – 0.01% 171
2025
Q2
$388K Sell
3,083
-4,428
-59% -$508K 0.01% 130
2025
Q1
$831K Buy
+7,511
New +$952K 0.03% 134

Other funds holding NBIX

SIH Partners's NBIX Position: Q3 2026 in Review

SIH Partners increased its Neurocrine Biosciences (NBIX) stake by 1.5% in Q3 2026, buying an estimated $7.56K and bringing the position to 3,130 shares worth $444K. The position accounts for ﹤0.01% of the portfolio, ranked #246.

SIH Partners first reported a position in NBIX in Q1 2025 and has held it in 7 quarters since. The position peaked at $831K in Q1 2025. 735 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • SIH Partners held 3,130 shares of Neurocrine Biosciences worth $444K as of Q3 2026.
  • SIH Partners bought 47 Neurocrine Biosciences shares in Q3 2026, an estimated $7.56K.
  • Neurocrine Biosciences made up ﹤0.01% of SIH Partners's portfolio in Q3 2026, its #246 holding.
  • SIH Partners first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 7 quarters since.
  • SIH Partners's Neurocrine Biosciences position peaked at $831K in Q1 2025.
  • 735 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on SIH Partners's 13F filing for Q3 2026, filed 16 Nov 2026.